You said it...a couple of days...this thing will be over and done with by next week. Shareholders dealing with this like its a non-issue. Go Fish
We think alike, dumped ARRY (failed study), lost a little $, but gained way more back with EXEL / ITCI. How about that !
Remember I retired in 2013, patients were still using Li+, but I did notice patients stopping it and getting other Rx. You have to do levels with Li+.
Anyone interested in a buy out will look twice with this failure.
now if we could get the cost of therapy...then we can estimate min & max Rev by adjusting the % penetration into the market.
Not sure, but here is more info
Number of New Cases and Deaths per 100,000: The number of new cases of kidney and renal pelvis cancer was 15.6 per 100,000 men and women per year. The number of deaths was 3.9 per 100,000 men and women per year. These rates are age-adjusted and based on 2008-2012 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 1.6 percent of men and women will be diagnosed with kidney and renal pelvis cancer at some point during their lifetime, based on 2010-2012 data.
Prevalence of This Cancer: In 2012, there were an estimated 375,925 people living with kidney and renal pelvis cancer in the United States.
Moved to EXEL, we'll see, already in the $. Look at their chart, they had a huge drop, but made a nice comeback. I am surprised ARRY didn't take a bigger hit. GLTA.
In my practice bipolar patients if not severe many times are on one drug, many on Lithium. And if they continue to progress they get a 2nd drug. This is not an easy condition to deal with. Many patient manipulate their meds because they tend to get euphoric when they are in a manic phase. Many anti depressants are used also, SSRIs - Zoloft, Prozac, SNRIs - Effexor, and Wellbutrin. I don't have a feel for how ITI007 will do in these studies ? Any thoughts on that?
The Phase 3 program in bipolar depression consists of two multicenter, randomized, double-blind, placebo-controlled clinical trials. The first Phase 3 study will evaluate ITI-007 as a monotherapy and the second Phase 3 study will evaluate ITI-007 as an adjunctive therapy with lithium or valproate. The Company plans to commence these studies later this year.
Well the offering was very close to the closing price of $6, "Shareholder friendly " and didn't seem to have too much of a negative effect. Besides the company only had 29.5 Million, now they will have plenty of cash to move forward. if the offering would have been sub-$5 , eg, $4.5 then that might be viewed as very negative and we would be Red today and that would have still been a bullish opportunity to jump into the stock that is headed higher either way. Growing pains...in this case " it hurts so good ".